Vitazi.ai Partners with Eye Associates to Enhance AI-Driven Retinal Screening Technology
On February 12, 2025, Vitazi.ai, Inc., a renowned innovator in the field of Oculomics, announced a partnership with Eye Associates of New Mexico, the largest ophthalmology organization in the state. Operating 11 clinics, three surgery centers, and 10 optical shops across New Mexico, Eye Associates serves between 1,400 and 1,500 patients daily. This collaboration aims to leverage artificial intelligence to revolutionize retinal diagnostics and improve early disease detection.
Oculomics, the study of the retina through an AI lens, is a rapidly evolving field that has the potential to detect systemic diseases, such as cardiovascular issues, neurodegenerative diseases, and diabetes, years before the onset of clinical symptoms. With this strategic collaboration, Dr. Jeffrey Wigdahl, PhD, Chief Technology Officer at Vitazi.ai, and his team of retinal researchers will focus on developing new tools within the OculoInsights™ platform, which is a state-of-the-art AI-driven retinal diagnostic and early disease detection tool designed for retinal specialists and healthcare providers.
In a statement, Dr. Jeremy Stueven, MD, MBA, founder and CEO of Vitazi.ai, expressed, "This agreement with Eye Associates of New Mexico brings us closer to a future where AI-powered retinal imaging can provide early and more accurate diagnoses, improving patient outcomes on a global scale." He continued to explain that by building a comprehensive platform of AI models relating to retinal health, they are not only advancing diagnostic capabilities but laying the groundwork for a revolution in accessible, AI-driven healthcare that transforms disease screening and preventive medicine.
The OculoInsights™ platform is designed to democratize access to modern diagnostic tools, enabling physicians to employ retinal biomarkers to identify diseases like Alzheimer’s, hypertension, and various metabolic disorders, often before they manifest clinically. Although Vitazi.ai currently cannot detect all these diseases, the partnership with Eye Associates will provide a robust dataset to aid in the research and development of additional Oculomics tools, with the ultimate goal of facilitating earlier interventions and enhancing patient care.
As a leading authority in Oculomics, Vitazi.ai is dedicated to pushing the boundaries of AI-driven healthcare innovation. The company envisions a future where retinal screening powered by AI becomes a standard, effective method for early disease detection, dramatically improving healthcare outcomes across patient populations. This partnership not only represents a significant advancement in technology but also showcases Vitazi.ai’s commitment to bettering public health through pioneering research.
For those interested in learning more about this exciting development, additional information is available at www.vitazi.ai. Media inquiries can be directed to Katheryn Sosa, MD at 1-833-4-VITAZI.
The implications of this partnership extend far beyond New Mexico, potentially setting a precedent for how healthcare providers can utilize AI tools in their practices globally. As the field of Oculomics grows, both Vitazi.ai and Eye Associates of New Mexico are positioned to lead the charge in integrating advanced technology into ophthalmic care, ensuring that patients receive the most accurate and timely diagnoses possible. With a focus on innovation and collaboration, they are paving the way for a new era in medical diagnostics.
Oculomics, the study of the retina through an AI lens, is a rapidly evolving field that has the potential to detect systemic diseases, such as cardiovascular issues, neurodegenerative diseases, and diabetes, years before the onset of clinical symptoms. With this strategic collaboration, Dr. Jeffrey Wigdahl, PhD, Chief Technology Officer at Vitazi.ai, and his team of retinal researchers will focus on developing new tools within the OculoInsights™ platform, which is a state-of-the-art AI-driven retinal diagnostic and early disease detection tool designed for retinal specialists and healthcare providers.
In a statement, Dr. Jeremy Stueven, MD, MBA, founder and CEO of Vitazi.ai, expressed, "This agreement with Eye Associates of New Mexico brings us closer to a future where AI-powered retinal imaging can provide early and more accurate diagnoses, improving patient outcomes on a global scale." He continued to explain that by building a comprehensive platform of AI models relating to retinal health, they are not only advancing diagnostic capabilities but laying the groundwork for a revolution in accessible, AI-driven healthcare that transforms disease screening and preventive medicine.
The OculoInsights™ platform is designed to democratize access to modern diagnostic tools, enabling physicians to employ retinal biomarkers to identify diseases like Alzheimer’s, hypertension, and various metabolic disorders, often before they manifest clinically. Although Vitazi.ai currently cannot detect all these diseases, the partnership with Eye Associates will provide a robust dataset to aid in the research and development of additional Oculomics tools, with the ultimate goal of facilitating earlier interventions and enhancing patient care.
As a leading authority in Oculomics, Vitazi.ai is dedicated to pushing the boundaries of AI-driven healthcare innovation. The company envisions a future where retinal screening powered by AI becomes a standard, effective method for early disease detection, dramatically improving healthcare outcomes across patient populations. This partnership not only represents a significant advancement in technology but also showcases Vitazi.ai’s commitment to bettering public health through pioneering research.
For those interested in learning more about this exciting development, additional information is available at www.vitazi.ai. Media inquiries can be directed to Katheryn Sosa, MD at 1-833-4-VITAZI.
The implications of this partnership extend far beyond New Mexico, potentially setting a precedent for how healthcare providers can utilize AI tools in their practices globally. As the field of Oculomics grows, both Vitazi.ai and Eye Associates of New Mexico are positioned to lead the charge in integrating advanced technology into ophthalmic care, ensuring that patients receive the most accurate and timely diagnoses possible. With a focus on innovation and collaboration, they are paving the way for a new era in medical diagnostics.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.